Laboratory of Innovative Toxicological Research and Analyses, Institute of Medical Studies, MedicalCollege, Rzeszo´w University, Al. mjr. W. Kopisto 2a, 35-959, Rzeszow, Poland.
Department of Regulatory and Forensic Toxicology, Institute of Medical Expertises, ul. Aleksandrowska 67/93, 91-205, Lodz, Poland.
Sci Rep. 2024 Mar 4;14(1):5293. doi: 10.1038/s41598-024-56057-7.
Chromium, which can currently only be considered pharmacologically active and not an essential element, is a very intriguing elemental impurity in final pharmaceutical products, especially traditional herbal medicinal products. This kind of traditional herbal medicinal product with Marshmallow root (Althaea officinalis L., radix) registered in the EU is widely used among the European population. The aim of this article is to propose a double regulatory strategy in assessing the human health risk of total chromium impurities in cough syrups with Marshmallow Root (Althaea officinalis) available in Polish pharmacies. We applied the strategy based on the requirements of the ICH Q3D (R1) guideline for the assessment of Cr impurities in final traditional herbal medicinal products with Marshmallow Root registered in the EU. Furthermore, we applied the strategy based on the concept of margin of exposure (MoE) considering Cr(VI) genotoxicity mode of action (MOA) and based on BMD for Cr(VI) as a point of departure (PoD). The total Cr content was in the range: 1.12-9.61 µg/L (in comparison with the ICH Q3D R1 guidelines: 1100 µg/g). Total Cr levels in a single dose were relatively high compared to raw results, but were not a threat to patients. Comparison of estimated results with oral PDE value for Cr in final drugs suggested by the ICH Q3D R1 guideline (10,700 µg/day) show that all the products analyzed were below this value (the highest result was 278.40 ng/day). Despite conservative assumptions, the MoE values obtained for Cr in daily dose for each Marshmallow Root cough syrup were above 10,000; therefore, exposure to Cr would not cause a health risk for specific population groups (children and adults). It can be summarized that each of the phytopharmaceuticals analysed with Marshmallow root available in Polish pharmacies does not represent a health hazard to patients. We confirm the safety of Cr impurities by applying a double regulatory strategy without the application of an expansive and demanding HPLC-ICP-MS technique for Cr speciation.
铬目前只能被认为具有药理活性,而非必需元素,但它是最终药物产品(尤其是传统草药药物)中一种非常有趣的元素杂质。在欧盟注册的含有药蜀葵根(Althaea officinalis L.,根)的这种传统草药药物在欧洲人群中广泛使用。本文的目的是提出一种双重监管策略,用于评估波兰药店提供的含有药蜀葵根(Althaea officinalis)的咳嗽糖浆中总铬杂质对人类健康的风险。我们应用了该策略,该策略基于 ICH Q3D(R1)指南中关于评估在欧盟注册的含有药蜀葵根的最终传统草药药物中 Cr 杂质的要求。此外,我们还应用了基于暴露界限(MOE)的策略,考虑 Cr(VI)遗传毒性作用模式(MOA)和基于 BMD 作为起点(PoD)的 Cr(VI)。总 Cr 含量在 1.12-9.61 µg/L 范围内(与 ICH Q3D R1 指南相比:1100 µg/g)。与原始结果相比,单次剂量的总 Cr 水平相对较高,但不会对患者构成威胁。用 ICH Q3D R1 指南中建议的最终药物中 Cr 的口服 PDE 值(10,700 µg/天)与估计结果进行比较,表明分析的所有产品均低于该值(最高结果为 278.40 ng/天)。尽管假设保守,但对于每种药蜀葵根咳嗽糖浆的每日剂量 Cr 获得的 MoE 值均高于 10,000;因此,暴露于 Cr 不会对特定人群(儿童和成人)造成健康风险。可以总结的是,波兰药店提供的每种含药蜀葵根的植物药物都不会对患者造成健康危害。我们通过应用双重监管策略而不是应用要求苛刻的 HPLC-ICP-MS 技术来对 Cr 进行形态分析来确认 Cr 杂质的安全性。